Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | TAGLN |
| Gene Name: | TAGLN |
| Protein Full Name: | Transgelin |
| Alias: | 22 kDa actin-binding protein; DKFZp686P11128; SM22; SM22-alpha; SMCC; Smooth muscle protein 22-alpha; TAGL; TAGLN1; Transgelin variant 2; WS3-10 |
| Mass (Da): | 22611 |
| Number AA: | 201 |
| UniProt ID: | Q01995 |
| Locus ID: | 6876 |
| COSMIC ID: | TAGLN |
| Gene location on chromosome: | 11q23.3 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 19625 |
| Percent of cancer specimens with mutations: | 0.15 |
| Normal role description: | Transgelin is an actin stress fibre binding protein that gels and stabilizes actin. It is involved in podosome formation and myocyte migration, vascular and visceral smooth muscle cell differentiation, and in the suppression of MMP9 and of tissue remodelling following muscle cell differentiation in the embryo. In adult tissues, it is thought to suppress tumour cell invasion through MMP-9 suppression, and to suppress the translocation of androgen receptors to the nucleus. It is involved in calcium interactions and contractile properties of the cell that may contribute to replicative senescence. It is overexpressed in senescent human fibroblasts and down-regulated in various types of cancers. |